MétaCan
Menu
Back to cohort
Record W4416667502 · doi:10.1186/s40834-025-00414-y

A drug-drug interaction study to evaluate the effects of strong CYP3A4 inducer on the pharmacokinetics of segesterone acetate and ethinyl estradiol in a contraceptive vaginal system

2025· article· en· W4416667502 on OpenAlexaboutno aff
Marlena Plagianos, Maud Lansiaux, Narender Kumar, Shelli Graham, Heather Sussman, Harvey Kushner, George W. Creasy, Brian Bernick, Lisa B. Haddad

Bibliographic record

VenueContraception and Reproductive Medicine · 2025
Typearticle
Languageen
FieldMedicine
TopicReproductive Health and Contraception
Canadian institutionsnot available
Fundersnot available
KeywordsPharmacokineticsEthinylestradiolCmaxCYP3A4Drug interactionConfidence intervalMenstrual cyclePregnancy

Abstract

fetched live from OpenAlex

BACKGROUND: In 2018, the US FDA approved a long-acting contraceptive vaginal system (CVS) releasing a new progestin, segesterone acetate (SA) and ethinyl estradiol (EE). As most progestins and EE used in hormonal contraceptives are metabolized via the CYP3A4 pathway, drug-drug interactions within the CYP3A4 network are a potential concern for contraceptive efficacy and/or safety. SA and EE systemic exposure could be reduced following administration of a strong CYP3A4 inducer such as rifampin, thus influencing risk of pregnancy or side effects. The study aimed to assess the pharmacokinetics of SA and EE from the CVS in healthy women when co-administered with rifampin. MATERIALS AND METHODS: This randomized, open-label, cross-over study was conducted at two Canadian sites to evaluate potential drug-drug interaction between rifampin (600 mg once daily) and the CVS releasing on average 150 µg of SA and 13 µg of EE daily. Blood samples were collected at predetermined time intervals after CVS insertion with and without concomitant Rifampin treatment. Serum concentrations of SA and EE were measured by validated LCMS/MS method. Concentrations were used to calculate pharmacokinetic parameters for comparison. RESULTS: Twenty-one healthy women were enrolled and randomized (1:1) to sequence A (CVS alone in treatment cycle 1; CVS + rifampin in treatment cycle 2) or sequence B (CVS + rifampin in treatment cycle 1; CVS alone in treatment cycle 2); 18 women completed the study. Rifampin co-treatment had no significant impact on PK parameters of SA. The 90% confidence intervals of geometric mean ratios (GMR) for AUC and Cmax were wholly contained within 0.8–1.25, supportive of bioequivalence. Serum concentrations of EE were significantly decreased: the GMR and 90% confidence intervals for AUC were 0.44 (0.39–0.50) and Cmax was 0.55 (0.47–0.65). No new or unexpected safety concerns were observed during the study conduct. CONCLUSIONS: We report a drug-drug interaction of rifampin on systemic exposure of EE but not SA. As the progestin seems to be the major driver of contraceptive efficacy, we do not expect co-administration of a CYP3A4 inducer to reduce contraceptive effectiveness. These results suggest that this CVS may be used with rifampin without additional precautions to prevent unintended pregnancy. TRIAL REGISTRATION: This trial was registered with ClincalTrials.gov Identifier NCT04290390.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.003
metaresearch head score (Gemma)0.002
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.794
Threshold uncertainty score0.681

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0030.002
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.001
Science and technology studies0.0000.001
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.026
GPT teacher head0.358
Teacher spread0.332 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueContraception and Reproductive MedicineSame topicReproductive Health and ContraceptionFrench-language works237,207